A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT ID: NCT02246621
Last Updated: 2026-02-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
493 participants
INTERVENTIONAL
2014-11-06
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer
NCT01151215
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
NCT02278120
Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy
NCT00754845
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
NCT00382070
Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.
NCT00287534
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Abemaciclib + NSAI
150 milligrams (mg) Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
Abemaciclib
Administered orally
Anastrozole
Administered orally
Letrozole
Administered orally
Placebo + NSAI
Placebo orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
Anastrozole
Administered orally
Letrozole
Administered orally
Placebo
Administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Abemaciclib
Administered orally
Anastrozole
Administered orally
Letrozole
Administered orally
Placebo
Administered orally
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have locoregionally recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease
* Have postmenopausal status
* Have either measurable disease or nonmeasurable bone-only disease
* Have a performance status ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale
* Have adequate organ function
* Have discontinued previous localized radiotherapy for palliative purposes or for lytic lesions at risk of fracture prior to randomization and recovered from the acute effects of therapy
* Are able to swallow capsules
Exclusion Criteria
* Have inflammatory breast cancer
* Have clinical evidence or a history of central nervous system (CNS) metastasis
* Are currently receiving or have previously received endocrine therapy for locoregionally recurrent or metastatic breast cancer
* Have received prior (neo)adjuvant endocrine therapy with a disease-free interval ≤12 months from completion of treatment
* Are currently receiving or have previously received chemotherapy for locoregionally recurrent or metastatic breast cancer
* Have received prior treatment with everolimus
* Have received prior treatment with any cyclin-dependent kinase (CDK) 4/6 inhibitor (or participated in any CDK4/6 inhibitor clinical trial for which treatment assignment is still blinded)
* Have initiated bisphosphonates or approved receptor activator of nuclear factor kappa-B ligand (RANK-L) targeted agents \<7 days prior to randomization
* Are currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study
* Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of randomization for a nonmyelosuppressive or myelosuppressive agent, respectively
* Have had major surgery within 14 days prior to randomization
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ironwood Cancer & Research Centers
Chandler, Arizona, United States
Highlands Oncology Group
Springdale, Arkansas, United States
CBCC Global Research, Inc.
Bakersfield, California, United States
California Cancer Associates Research and Excellence
Fresno, California, United States
TRIO-US (Translational Research in Oncology-US)
Los Angeles, California, United States
Central Coast Medical Oncology Corporation
Los Angeles, California, United States
Orlando Health, Inc
Los Angeles, California, United States
North Valley Hematology/Oncology Medical Group
Los Angeles, California, United States
UCLA Hematology/Oncology - Parkside
Santa Monica, California, United States
Holy Cross Hospital
Fort Lauderdale, Florida, United States
Lakes Research, LLC
Miami Lakes, Florida, United States
Candler Medical Oncology Practice - Statesboro
Savannah, Georgia, United States
Candler Medical Oncology Practice - Statesboro
Savannah, Georgia, United States
Mayo Clinic in Rochester, Minnesota
Rochester, Minnesota, United States
Nebraska Hematology-Oncology, P.C.
Lincoln, Nebraska, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Mount Sinai Cancer Center
New York, New York, United States
University of Tennessee Medical Center
Knoxville, Tennessee, United States
Oncology Consultants P.A.
Houston, Texas, United States
Joe Arrington Cancer Center
Lubbock, Texas, United States
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
St Vincent's Hospital
Sydney, New South Wales, Australia
Sydney Adventist Hospital
Wahroonga, New South Wales, Australia
Mater Adult Hospital Brisbane
South Brisbane, Queensland, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
The Queen Elizabeth Hospital
Woodville, South Australia, Australia
Barwon Health - The Geelong Hospital
Geelong, Victoria, Australia
St. John of God Murdoch Hospital
Murdoch, Western Australia, Australia
Medizinische Universitaet Graz
Graz, Styria, Austria
Medizinische Universitaet Innsbruck
Innsbruck, Tyrol, Austria
Ordensklinikum Linz
Linz, Upper Austria, Austria
Medizinische Universität Wien
Vienna, Vienna, Austria
Universitaetsklinikum Allgemeines Krankenhaus Wien
Vienna, Vienna, Austria
Iridium Kankernetwerk Wilrijk en Antwerp
Wilrijk, Antwerpen, Belgium
Cliniques universitaires Saint-Luc
Brussels, Brussels Capital, Belgium
Institut Jules Bordet
Anderlecht, Bruxelles-Capitale, Région de, Belgium
Grand Hopital de Charleroi-Site Notre-Dame
Charleroi, , Belgium
CHU UCL Namur/Site Sainte Elisabeth
Namur, , Belgium
AZ Delta
Roeselare, , Belgium
Cross Cancer Institute
Edmonton, Alberta, Canada
Lakeridge Health
Oshawa, Ontario, Canada
The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
Princess Margaret Hospital (Ontario)
Toronto, Ontario, Canada
Hopital Notre Dame
Montreal, Quebec, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal (CIUSSS NÎM) - H -T
Montreal, Quebec, Canada
Hopital du Saint-Sacrement
Québec, , Canada
Polyclinique Bordeaux Nord
Bordeaux, Aquitaine, France
Centre Leon Berard
Lyon, Auvergne-Rhône-Alpes, France
Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan
Brest, Brittany Region, France
Centre Georges François Leclerc
Dijon, Côte-d'Or, France
Centre Hospitalier de Saint-Brieuc - Hôpital Yves Le Foll
Saint-Brieuc, Côtes-d'Armor, France
Centre de Cancérologie du Grand Montpellier
Montpellier, Languedoc-Roussillon, France
Institut de Cancérologie de l'Ouest
Saint-Herblain, Loire-Atlantique, France
Polyclinique de Gentilly
Nancy, Meurthe-et-Moselle, France
CHD Vendee
La Roche-sur-Yon, Vendée, France
CHU de Besancon Hopital Jean Minjoz
Besançon, , France
Klinikum Ludwigsburg
Ludwigsburg, Baden-Wurttemberg, Germany
Universitätsklinikum Ulm
Ulm, Baden-Wurttemberg, Germany
Klinikum Rechts der Isar der TU München
München, Bavaria, Germany
Helios Dr. Horst Schmidt Kliniken
Wiesbaden, Hesse, Germany
Marien-Hospital Düsseldorf
Düsseldorf, North Rhine-Westphalia, Germany
Lübecker Onkologische Schwerpunktpraxis
Lübeck, Schleswig-Holstein, Germany
Facharztzentrum Eppendorf
Hamburg, , Germany
Kath. Marienkrankenhaus gGmbH
Hamburg, , Germany
Alexandra Hospital
Athens, Attikí, Greece
Rabin Medical Center
Petah Tikva, Central District, Israel
Sheba Medical Center
Ramat Gan, Central District, Israel
Kaplan Medical Center
Rehovot, Central District, Israel
Hadassah Medical Center
Jerusalem, Jerusalem, Israel
Soroka Medical Center
Beersheba, , Israel
Meir Medical Center
Kfar Saba, , Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, , Israel
Rambam Health Care Campus
Haifa, Ḥeifā, Israel
Ospedale Perrino
Brindisi, BR, Italy
Azienda Ospedaliero Universitaria di Ferrara
Cona, Ferrara, Italy
Ospedale San Martino
Genoa, Liguria, Italy
Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia
Candiolo, Torino, Italy
Nuovo Ospedale di Prato-S.Stefano
Prato, Tuscany, Italy
Ospedale Sacro Cuore Don G. Calabria
Negrar, Verona, Italy
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo, , Italy
Ospedale Bellaria - Azienda USL di Bologna
Bologna, , Italy
Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte
Messina, , Italy
Policlinico Ospedale S. Andrea
Roma, , Italy
Azienda Ospedaliera Santa Maria Terni
Terni, , Italy
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan
Chiba cancer center
Chiba, Chiba, Japan
National Hospital Organization Shikoku Cancer Center
Matsuyama, Ehime, Japan
National Hospital Organization Hokkaido Cancer Center
Sapporo, Hokkaido, Japan
Hyogo College of Medicine
Nishinomiya, Hyōgo, Japan
Kanagawa cancer center
Yokohama, Kanagawa, Japan
Niigata Cancer Center Hospital
Niigata, Niigata, Japan
Kindai University Hospital- Osakasayama Campus
Ōsaka-sayama, Osaka, Japan
Saitama Prefectural Cancer Center
Kitaadachi-Gun, Saitama, Japan
Shizuoka Cancer Center
Nakatogari, Shizuoka, Japan
Jichi Medical University Hospital
Shimotsuke, Tochigi, Japan
Tokyo Met Cancer & Infectious Diseases Center Komagome Hp
Bunkyo-ku, Tokyo, Japan
Japanese Foundation for Cancer Research
Koto, Tokyo, Japan
Tokyo Medical University Hospital
Shinjuku-ku, Tokyo, Japan
National Hospital Organization Kyushu Cancer Center
Fukuoka, , Japan
Hiroshima City Hospital
Hiroshima, , Japan
Kyoto University Hospital
Kyoto, , Japan
National Hospital Organization Osaka Medical Center
Osaka, , Japan
Osaka International Cancer Institute
Osaka, , Japan
Clinica Oncológica San Francisco
Torreón, Coahuila, Mexico
Superare Centro de Infusion
México, Federal District, Mexico
Fundacion Rodolfo Padilla AC
León, Guanajuato, Mexico
Hospital Civil Fray Antonio Alcalde
Guadalajara, Jalisco, Mexico
Hospital La Raza
Mexico City, Mexico City, Mexico
Grupo Medico Camino Sc
Mexico City, Mexico City, Mexico
Centro Oncologico Belenus
Cuernavaca, Morelos, Mexico
Centro de Estudios Y Prevencion Del Cancer
Juchitán de Zaragoza, Oaxaca, Mexico
Cancerología
Colinas Del Cimatario, Querétaro, Mexico
Haga Ziekenhuis locatie Leyweg
The Hague, South Holland, Netherlands
Leids Universitair Medisch Centrum
Leiden, , Netherlands
Auckland City Hospital
Auckland, , New Zealand
Arkhangelsk Clinical Oncological Dispensary
Arkhangelsk, Arkhangelskaya oblast, Russia
Fed State Budgetary Inst "N.N. Blokhin Med Center of Oncology" MHRF
Moscow, Moscow, Russia
European Medical Center
Moscow, Russian Federation, Russia
Clinic Complex
Saint Petersburg, Russian Federation, Russia
Republic Oncology Dispensary of MoH of Republic Tatarstan
Kaznan, Russia, Russia
Saint-Petersburg City Clinical Oncology Dispensary
Saint Petersburg, , Russia
Rosmedtech Scientific Research Institute of Oncology
Saint Petersburg, , Russia
Onkologicky Ustav sv. Alzbety
Bratislava, Bratislava Region, Slovakia
Vychodoslovensky Onkologicky ustav a.s.
Košice, Košice Region, Slovakia
Inha University Hospital
Incheon, Incheon-gwangyeoksi [Incheon], South Korea
National Cancer Center
Goyang-si, Kyǒnggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam, Kyǒnggi-do, South Korea
Seoul National University Hospital
Seoul, Seoul-teukbyeolsi [Seoul], South Korea
Severance Hospital, Yonsei University Health System
Seoul, Seoul-teukbyeolsi [Seoul], South Korea
Asan Medical Center
Seoul, Seoul-teukbyeolsi [Seoul], South Korea
Samsung Medical Center
Seoul, Seoul-teukbyeolsi [Seoul], South Korea
Kyungpook National University Chilgok Hospital
Daegu, Taegu-Kwangyǒkshi, South Korea
Ulsan University Hospital
Ulsan, Ulsan-Kwangyǒkshi, South Korea
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Badajoz, , Spain
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Barcelona, , Spain
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Donostia / San Sebastian, , Spain
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Lleida, , Spain
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Madrid, , Spain
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Valencia, , Spain
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Gävle, , Sweden
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Örebro, , Sweden
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Västerås, , Sweden
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Beidou, , Taiwan
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Kuei Shan Hsiang, , Taiwan
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Taichung, , Taiwan
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Taipei, , Taiwan
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Zhonghe, , Taiwan
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Ankara, , Turkey (Türkiye)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Edirne, , Turkey (Türkiye)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Malatya, , Turkey (Türkiye)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Bebbington, , United Kingdom
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Cambridge, , United Kingdom
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Manchester, , United Kingdom
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tredan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017 Nov 10;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2.
Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019 Jan 17;5:5. doi: 10.1038/s41523-018-0097-z. eCollection 2019.
Hong J, Chen T, Ouyang L, Du N, Li A, Zhou Z, Zhang H, Xia Z, Meng J. Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2- advanced breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2024 Apr;24(4):559-566. doi: 10.1080/14737167.2024.2330542. Epub 2024 Mar 20.
Rugo HS, Harmer V, O'Shaughnessy J, Jhaveri K, Tolaney SM, Cardoso F, Bardia A, Maheshwari VK, Tripathi S, Haftchenary S, Pathak P, Fasching PA. Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison. Ther Adv Med Oncol. 2023 Feb 24;15:17588359231152843. doi: 10.1177/17588359231152843. eCollection 2023.
Takahashi M, Tokunaga E, Mori J, Tanizawa Y, van der Walt JS, Kawaguchi T, Goetz MP, Toi M. Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Breast Cancer. 2022 Jan;29(1):174-184. doi: 10.1007/s12282-021-01295-0. Epub 2021 Oct 18.
Goetz MP, Okera M, Wildiers H, Campone M, Grischke EM, Manso L, Andre VAM, Chouaki N, San Antonio B, Toi M, Sledge GW Jr. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Res Treat. 2021 Apr;186(2):417-428. doi: 10.1007/s10549-020-06029-y. Epub 2021 Jan 3.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol: JPBM Protocol (a)
Document Type: Study Protocol: JPBM Protocol (b)
Document Type: Study Protocol: JPBM Protocol
Document Type: Statistical Analysis Plan: SAP V5 Addendum
Document Type: Statistical Analysis Plan: SAP V5
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I3Y-MC-JPBM
Identifier Type: OTHER
Identifier Source: secondary_id
2014-001502-18
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
15417
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.